People · Operator
Named in public records as an officer, director or promoter · active 2009–2012 · Other Health Care, Biotechnology, Other, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| AliveCor, Inc. | — | Other Health Care | Series C | $105.9M | $1.2B | 2011 |
| XDx, Inc. | — | Biotechnology | Series B | $44.5M | $879.9M | 2010 |
| Bioimagene Inc | — | Biotechnology | Series A | $12.0M | $433.8M | 2009 |
| Proteogenix Inc | — | Biotechnology | Series A | $8.0M | $144.6M | 2009 |
| Abunda Corp | — | Other Health Care | Series A | $4.1M | $83.5M | 2009 |
| Proventys, Inc | — | Other | Seed | $3.3M | $60.4M | 2010 |
| Ikano Therapeutics Inc. | — | Pharmaceuticals | Pre-Seed | $893K | $42.2M | 2009 |
G. Steven Burrill at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside G. Steven Burrill on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Fred Cohen | 2 | 12 |
| Vijay Lathi | 2 | 8 |
| Ralph Snyderman | 2 | 4 |
| David Levison | 2 | 3 |
| Brook Byers | 1 | 13 |
| Vinod Khosla | 1 | 12 |
| Michael Goldberg | 1 | 11 |
| Ganesh Kishore | 1 | 7 |
| Yatin Mundkur | 1 | 7 |
| Bryant Fong | 1 | 5 |
| Ajit Singh | 1 | 5 |
| John Dean | 1 | 5 |
| Toby Cosgrove | 1 | 4 |
| Joseph Keegan | 1 | 4 |
| William Hagstrom | 1 | 4 |
| Ryan Phillips | 1 | 3 |
| Peter Altman | 1 | 3 |
| Charles Constanti | 1 | 3 |
| Fred G. Cohen | 1 | 3 |
| Mike Allen | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.